Trends In Biopharmaceutical Clinical Trials After Medicare Drug Price Negotiation
Abstract
The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices for selected drugs, with implications for innovation. Using ClinicalTrials.gov data on biopharmaceutical trials initiated during 2015-24, we found that overall trial activity remained stable, returning to prepandemic levels, but manufacturers with drugs subject to negotiation initiated fewer trials, particularly in certain cancers.
Fields of Study & Subjects
Pharmaceutical Economics and Policy
Economic and Financial Impacts of Cancer
Health Systems
Economic Evaluations
Quality of Life
Publication details
- Journal / source
- Health Affairs
- Publisher
- Health Affairs Publishing, LLC
- Volume
- 45
- Issue
- 1
- Pages
- 48–53
- Publication date
- 1 January 2026
- Language
- EN